cancer

028 — Nirogacestat For Desmoid Tumors, Pirtobrutinib for CLL/SLL, Enfortumab Vedotin With Pembrolizumab for UC, Lisocabtagene Maraleucel for CLL/SLL, Xanomeline-trospium for Schizophrenia, Roflumilast for AD

Here is information on the latest US FDA approvals, the week of November 20 -  December 1, 2023Nirogacestat (Ogsiveo) For Desmoid TumorsThe FDA has approved nirogacestat (Ogsiveo) tablets for adult…

Continue Reading028 — Nirogacestat For Desmoid Tumors, Pirtobrutinib for CLL/SLL, Enfortumab Vedotin With Pembrolizumab for UC, Lisocabtagene Maraleucel for CLL/SLL, Xanomeline-trospium for Schizophrenia, Roflumilast for AD

027 — Capivasertib for Breast Cancer, Repotrectinib for NSCLC, Enzalutamide for Prostate Cancer, Pembrolizumab for Stomach Cancer, Hypertension Device

Here is information on the latest US FDA approvals, the week of November 13 -  November 17, 2023 Capivasertib (Truqap) for Breast CancerThe FDA has approved capivasertib (Truqap) in combination…

Continue Reading027 — Capivasertib for Breast Cancer, Repotrectinib for NSCLC, Enzalutamide for Prostate Cancer, Pembrolizumab for Stomach Cancer, Hypertension Device

026 — Tirzepatide for Obesity, Ixchiq Chikungunya Vaccine, fruquintinib for mCRC, Adzynma (ADAMTS13, recombinant-krhn) for cTTP

Here is information on the latest US FDA approvals, the week of November 6 -  November 10, 2023Tirzepatide (Zepbound) for Adults With ObesityThe FDA has approved Zepbound (tirzepatide) injection for…

Continue Reading026 — Tirzepatide for Obesity, Ixchiq Chikungunya Vaccine, fruquintinib for mCRC, Adzynma (ADAMTS13, recombinant-krhn) for cTTP

025 — Pembrolizumab, Secukinumab, Ustekinumab biosimilar, Vonoprazan, Abatacept, Exa-cel

Pembrolizumab (Keytruda) for Metastatic Biliary Tract CancerThe FDA has granted approval for pembrolizumab (Keytruda) in combination with gemcitabine and cisplatin for the treatment of patients diagnosed with locally advanced unresectable…

Continue Reading025 — Pembrolizumab, Secukinumab, Ustekinumab biosimilar, Vonoprazan, Abatacept, Exa-cel

024 — Loqtorzi, Vabysmo, Omvoh, Vamorolone, Tibsovo, FluMist

Here is information on the latest US FDA approvals, the week of October  23 -  October 27, 2023 Loqtorzi (toripalimab-tpzi) for Nasopharyngeal Carcinoma The FDA has approved Loqtorzi (toripalimab-tpzi), a…

Continue Reading024 — Loqtorzi, Vabysmo, Omvoh, Vamorolone, Tibsovo, FluMist

023 — Bimzelx (bimekizumab); Keytruda (Pembrolizumab); Opdivo (nivolumab); Zilbrysq (zilucoplan); Cabtreo (IDP-126); Penbraya; Voxzogo (vosoritide); Qlosi (pilocarpine); Maxigesic IV (paracetomol/ibuprofen); Xphozah (tenapanor); Zymfentra (SC infliximab biosimilar)

Here is information on the latest US FDA approvals, the week of October  16 -  October 20, 2023 Bimzelx (bimekizumab) for Moderate-to-Severe Plaque Psoriasis The FDA has approved BIMZELX® (bimekizumab-bkzx)…

Continue Reading023 — Bimzelx (bimekizumab); Keytruda (Pembrolizumab); Opdivo (nivolumab); Zilbrysq (zilucoplan); Cabtreo (IDP-126); Penbraya; Voxzogo (vosoritide); Qlosi (pilocarpine); Maxigesic IV (paracetomol/ibuprofen); Xphozah (tenapanor); Zymfentra (SC infliximab biosimilar)

022 — Velsipity (Etrasimod) for UC; Braftovi (encorafenib) and Mektovi (binimetinib) for NSCLC; Patisiran in ATTR amyloidosis; Digital Health Advisory Committee

Here is information on the latest US FDA approvals, the week of October  9 –  October 13, 2023Velsipity (Etrasimod) for UCThe FDA has approved Velsipity (etrasimod) for treating moderate to…

Continue Reading022 — Velsipity (Etrasimod) for UC; Braftovi (encorafenib) and Mektovi (binimetinib) for NSCLC; Patisiran in ATTR amyloidosis; Digital Health Advisory Committee

020 — Ryzumvi Mydriasis Reversal Drops, Exxua for MDD, Likmez Metronidazole Liquid Formulation, DNA Test for Hereditary Cancers, Tofidence Actemra Biosimilar, Pompe Disease Combination Therapy, Subcutaneous Entyvio, NurOwn in ALS

Here is information on the latest US FDA approvals, the week of September 25 –  September 29, 2023Ryzumvi (Phentolamine Ophthalmic Solution) for Dilated PupilsThe FDA has approved Ryzumvi (phentolamine ophthalmic…

Continue Reading020 — Ryzumvi Mydriasis Reversal Drops, Exxua for MDD, Likmez Metronidazole Liquid Formulation, DNA Test for Hereditary Cancers, Tofidence Actemra Biosimilar, Pompe Disease Combination Therapy, Subcutaneous Entyvio, NurOwn in ALS

019 — Jardiance (empagliflozin) for CKD, Welireg (belzutifan) for RCC, Tevimbra (tislelizumab) for Esophageal Squamous Cell Carcinoma, Neffy Epinephrine Nasal Spray

00:00:00  Here is information on the latest US FDA approvals, the week of September 18 –  September 22, 2023.Jardiance (empagliflozin) for CKDThe FDA has approved a new indication for Jardiance…

Continue Reading019 — Jardiance (empagliflozin) for CKD, Welireg (belzutifan) for RCC, Tevimbra (tislelizumab) for Esophageal Squamous Cell Carcinoma, Neffy Epinephrine Nasal Spray

018 — Ojjaara for Anemia in Myelofibrosis, Resmetirom for NASH, COVID-19 Vaccine Update, Phenylephrine, Patisiran in ATTR-CM

Here is information on the latest US FDA approvals, the week of September 11 –  September 15, 2023.FDA Approves Ojjaara (Momelotinib) for Anemia in MyelofibrosisThe FDA has approved Ojjaara (momelotinib)…

Continue Reading018 — Ojjaara for Anemia in Myelofibrosis, Resmetirom for NASH, COVID-19 Vaccine Update, Phenylephrine, Patisiran in ATTR-CM